nach oben

Journal of Nuclear Cardiology

Erschienen in:

02.01.2019 | Original Article

Diagnostic performance of F-18 FDG PET for detection of cardiac sarcoidosis; A systematic review and meta-analysis

verfasst von: Seong-Jang Kim, MD, PhD, Kyoungjune Pak, MD, PhD, Keunyoung Kim, MD

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

The purpose of the current study was to investigate the diagnostic performance of F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for diagnosis of cardiac sarcoidosis (CS) through a systematic review and meta-analysis.

Methods

The PubMed and EMBASE database, from the earliest available date of indexing through 31 March 31, 2018, were searched for studies evaluating the diagnostic performance of F-18 FDG PET or PET/CT for CS. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR−), and constructed summary receiver operating characteristic (SROC) curves.

Results

Across 17 studies (891 patients), the pooled sensitivity was 0.84 [95% confidence interval (95% CI) 0.71-0.91] with heterogeneity (I² = 77.5) and a pooled specificity of 0.83 (95% CI 0.74-0.89) with heterogeneity (I² = 80.0). Likelihood ratio (LR) syntheses gave an overall LR+ of 4.9 (95% CI 3.3-7.3) and LR− of 0.2 (95% CI 0.11-0.35). The pooled diagnostic odds ratio was 27 (95% CI 14-55). Hierarchical SROC curve indicates that the area under the curve was 0.90 (95% CI 0.87-0.92). Meta-regression showed that combined myocardial perfusion imaging was the source of heterogeneity.

Conclusion

The current meta-analysis showed the moderate sensitivity and specificity of F-18 FDG PET or PET/CT for diagnosis of CS. The presence of combined myocardial perfusion imaging could improve diagnostic accuracy of F-18 FDG PET or PET/CT for diagnosis of CS. At present, the literature regarding the use of F-18 FDG PET for detection of CS remains limited; thus, further large multicenter studies would be necessary to substantiate the diagnostic accuracy of F-18 FDG PET for diagnosis of CS.

Nur mit Berechtigung zugänglich

Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997;336:1224-34.PubMed

Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-77.PubMedPubMedCentral

Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis 2010;52:336-46.PubMed

Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC, et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm 2012;9:884-91.PubMed

Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978;58:1204-11.PubMed

Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest 1993;103:253-8.PubMed

Birnie DH, Nery PB, Ha AC, Beanlands RS. Cardiac sarcoidosis. J Am Coll Cardiol 2016;68:411-21.PubMed

Robert WC, McAllister HA, Ferrans VJ. Sarcoidosis of the heart. Am J Med 1977;63:86-108.

Leone O, Veinot JP, Angelini A, Baandrup UT, Basso C, Berry G, et al. 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol 2012;21:245-74.PubMed

10.

Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: Evaluation of endomyocardial biopsies. Am Heart J 1999;138:299-302.PubMed

11.

Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord 2007;27:89-102.

12.

Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of ¹⁸F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012;53:241-8.PubMed

13.

Ishida Y, Yoshinaga K, Miyagawa M, Moroi M, Kondoh C, Kiso K, et al. Recommendations for ¹⁸F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology recommendations. Ann Nucl Med 2014;28:393-403.PubMed

14.

Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, et al. Focal uptake on ¹⁸F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005;26:1538-43.PubMed

15.

Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329-36.PubMed

16.

Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36.PubMed

17.

Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: A single indicator of test performance. J Clin Epidemiol 2003;56:1129-35.PubMed

18.

Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994;309:1351-5.PubMedPubMedCentral

19.

Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58:882-93.PubMed

20.

Hamza TH, van Houwelingen HC, Stijnen T. The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol 2008;61:41-51.PubMed

21.

Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982-90.PubMed

22.

Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med 2001;20:2865-84.PubMed

23.

Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999;282:1061-6.PubMed

24.

Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzsolt F. A likelihood ratio approach to meta-analysis of diagnostic studies. J Med Screen 2003;10:47-51.PubMed

25.

Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM, Cochrane Diagnostic Test Accuracy Working Group. Systematic reviews of diagnostic test accuracy. Ann Intern Med 2008;149:889-97.PubMedPubMedCentral

26.

Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M, et al. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol 2014;21:925-39.PubMed

27.

Ambrosini V, Zompatori M, Fasano L, Nanni C, Nava S, Rubello D, Fanti S. ¹⁸F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis: Results of a preliminary prospective study. Clin Nucl Med 2013;38:e171-7.PubMed

28.

Gormsen LC, Haraldsen A, Kramer S, Dias AH, Kim WY, Borghammer P. A dual tracer ⁶⁸Ga-DOTANOC PET/CT and ¹⁸F-FDG PET/CT pilot study for detection of cardiac sarcoidosis. EJNMMI Res 2016;6:52.PubMedPubMedCentral

29.

Ito K, Okazaki O, Morooka M, Kubota K, Minamimoto R, Hiroe M. Visual findings of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with cardiac sarcoidosis. Intern Med 2014;53:2041-9.PubMed

30.

Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting ¹⁸F-FDG PET–CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009;16:801-10.PubMed

31.

Manabe O, Yoshinaga K, Ohira H, Sato T, Tsujino I, Yamada A, et al. Right ventricular ¹⁸F-FDG uptake is an important indicator for cardiac involvement in patients with suspected cardiac sarcoidosis. Ann Nucl Med 2014;28:656-63.PubMed

32.

Momose M, Fukushima K, Kondo C, Serizawa N, Suzuki A, Abe K, et al. Diagnosis and detection of myocardial injury in active cardiac sarcoidosis—significance of myocardial fatty acid metabolism and myocardial perfusion mismatch. Circ J 2015;79:2669-76.PubMed

33.

Norikane T, Yamamoto Y, Maeda Y, Noma T, Dobashi H, Nishiyama Y. Comparative evaluation of ¹⁸F-FLT and ¹⁸F-FDG for detecting cardiac and extra-cardiac thoracic involvement in patients with newly diagnosed sarcoidosis. EJNMMI Res 2017;7:69.PubMedPubMedCentral

34.

Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, et al. Myocardial imaging with ¹⁸F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008;35:933-41.PubMed

35.

Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting ¹⁸F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989-98.PubMed

36.

Schildt JV, Loimaala AJ, Hippeläinen ET, Ahonen AA. Heterogeneity of myocardial 2-[¹⁸F]fluoro-2-deoxy-d-glucose uptake is a typical feature in cardiac sarcoidosis: A study of 231 patients. Eur Heart J Cardiovasc Imaging 2018;19:293-8.PubMed

37.

Soussan M, Brillet PY, Nunes H, Pop G, Ouvrier MJ, Naggara N, et al. Clinical value of a high-fat and low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. J Nucl Cardiol 2013;20:120-7.PubMed

38.

Tahara N, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging 2010;3:1219-28.PubMed

39.

Yokoyama R, Miyagawa M, Okayama H, Inoue T, Miki H, Ogimoto A, et al. Quantitative analysis of myocardial ¹⁸F-fluorodeoxyglucose uptake by PET/CT for detection of cardiac sarcoidosis. Int J Cardiol 2015;195:180-7.PubMed

40.

Boerman OC, Rennen H, Oyen WJ, Corstens FH. Radiopharmaceuticals to image infection and inflammation. Semin Nucl Med 2001;31:286-95.PubMed

41.

Zhuang H, Alavi A. 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002;32:47-59.PubMed

42.

Love C, Tomas MB, Tronco GG, Palestro CJ. FDG PET of infection and inflammation. Radiographics 2005;25:1357-68.PubMed

43.

Takeda N, Yokoyama I, Hiroi Y, Sakata M, Harada T, Nakamura F, et al. Positron emission tomography predicted recovery of complete A-V nodal dysfunction in a patient with cardiac sarcoidosis. Circulation 2002;105:1144-5.PubMed

44.

Ishimaru S, Tsujino I, Sakaue S, Oyama N, Takei T, Tsukamoto E, et al. Combination of ¹⁸F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:234-5.PubMed

45.

Tang R, Wang JT, Wang L, Le K, Huang Y, Hickey AJ, et al. Impact of patient preparation on the diagnostic performance of ¹⁸F-FDG PET in cardiac sarcoidosis: A systematic review and meta-analysis. Clin Nucl Med 2016;41:e327-39.PubMed

46.

Ding HJ, Shiau YC, Wang JJ, Ho ST, Kao A. The influences of blood glucose and duration of fasting on myocardial glucose uptake of [¹⁸F]fluoro-2-deoxy-d-glucose. Nucl Med Commun 2002;23:961-5.PubMed

47.

Williams G, Kolodny GM. Suppression of myocardial ¹⁸F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. Am J Roentgenol 2008;190:W151-6.

48.

Guideline for diagnosis of cardiac sarcoidosis: Study report on diffuse pulmonary diseases. Tokyo: Ministry of Health, Labour and Welfare; 1993. p. 23-4.

49.

Skali H, Schulman AR, Dorbala S. ¹⁸F-FDG PET/CT for the assessment of myocardial sarcoidosis. Curr Cardiol Rep 2013;15:352.PubMedPubMedCentral

50.

Dilsizian V, Bacharach SL, Beanlands RS, et al. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J Nucl Cardiol 2016;23:1187-226.PubMed

51.

Lee PI, Cheng G, Alavi A. The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis. J Nucl Cardiol 2017;24:19-28.PubMed

52.

Ahmadian A, Pawar S, Govender P, Berman J, Ruberg FL, Miller EJ. The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis. J Nucl Cardiol 2017;24:413-24.PubMed

53.

Muser D, Santangeli P, Castro SA, et al. Prognostic role of serial quantitative evaluation of ¹⁸F-fluorodeoxyglucose uptake by PET/CT in patients with cardiac sarcoidosis presenting with ventricular tachycardia. Eur J Nucl Med Mol Imaging 2018;45:1394-404.PubMed

54.

Flores RJ, Flaherty KR, Jin Z, Bokhari S. The prognostic value of quantitating and localizing F-18 FDG uptake in cardiac sarcoidosis. J Nucl Cardiol 2018. https://doi.org/10.1007/s12350-018-01504-y (Epub ahead of print0.CrossRefPubMed

Titel: Diagnostic performance of F-18 FDG PET for detection of cardiac sarcoidosis; A systematic review and meta-analysis
verfasst von: Seong-Jang Kim, MD, PhD
Kyoungjune Pak, MD, PhD
Keunyoung Kim, MD
Publikationsdatum: 02.01.2019
Verlag: Springer International Publishing
Erschienen in: Journal of Nuclear Cardiology / Ausgabe 6/2020
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-018-01582-y

Neu im Fachgebiet Kardiologie

25.04.2024 | Hypotonie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Diagnostic performance of F-18 FDG PET for detection of cardiac sarcoidosis; A systematic review and meta-analysis

Abstract

Objective

Methods

Results

Conclusion

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2020

What is this Image? 2020: Image 3 Result Pure septal myocardial infarction

Same day comparison of PET/CT and PET/MR in patients with cardiac sarcoidosis

Right ventricular sympathetic dysfunction in arrhythmogenic right ventricular cardiomyopathy: News or noise?

Increased myocardial 18F-FDG uptake as a marker of Doxorubicin-induced oxidative stress

68Ga-labeled exendin-4 to image cardiac repair after myocardial infarction: From lizard venom to laboratory and beyond

Imaging cardiac sarcoidosis with FDG-PET: Take a look at the right side!

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie